Volume | 19,667 |
|
|||||
News | - | ||||||
Day High | 1.33 | Low High |
|||||
Day Low | 1.26 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Clearside Biomedical Inc | CLSD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.32 | 1.26 | 1.33 | 1.34 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
93 | 19,667 | $ 1.31 | $ 25,672 | - | 0.650101 - 2.12 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:33:32 | 100 | $ 1.28 | USD |
Clearside Biomedical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
95.64M | 74.72M | - | 8.23M | -32.49M | -0.43 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Clearside Biomedical News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLSD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.28 | 1.48 | 1.24 | 1.35 | 258,384 | 0.00 | 0.00% |
1 Month | 1.66 | 1.73 | 1.10 | 1.34 | 296,911 | -0.38 | -22.89% |
3 Months | 1.25 | 2.12 | 1.10 | 1.55 | 386,672 | 0.03 | 2.40% |
6 Months | 0.745 | 2.12 | 0.650101 | 1.39 | 284,792 | 0.535 | 71.81% |
1 Year | 1.09 | 2.12 | 0.650101 | 1.30 | 198,410 | 0.19 | 17.43% |
3 Years | 2.97 | 7.73 | 0.650101 | 3.42 | 559,449 | -1.69 | -56.90% |
5 Years | 1.26 | 7.73 | 0.56 | 2.84 | 584,487 | 0.02 | 1.59% |
Clearside Biomedical Description
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision. |